MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches

Joseph Markowitz, Zachary Abrams, Naduparambil K. Jacob, Xiaoli Zhang, John N. Hassani, Nicholas Latchana, Lai Wei, Kelly E. Regan, Taylor R. Brooks, Sarvani R. Uppati, Kala M. Levine, Tanios Bekaii-Saab, Kari L. Kendra, Gregory B. Lesinski, J. Harrison Howard, Thomas Olencki, Philip R. Payne, William E. Carson

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: MicroRNAs (miRNAs) are short noncoding RNAs that function to repress translation of mRNA transcripts and contribute to the development of cancer. We hypothesized that miRNA array-based technologies work best for miRNA profiling of patient-derived plasma samples when the techniques and patient populations are precisely defined. Methods: Plasma samples were obtained from five sources: melanoma clinical trial of interferon and bortezomib (12), purchased normal donor plasma samples (four), gastrointestinal tumor bank (nine), melanoma tumor bank (ten), or aged-matched normal donors (eight) for the tumor bank samples. Plasma samples were purified for miRNAs and quantified using NanoString® arrays or by the company Exiqon. Standard biostatistical array approaches were utilized for data analysis and compared to a rank-based analytical approach. Results: With the prospectively collected samples, fewer plasma samples demonstrated visible hemolysis due to increased attention to eliminating factors, such as increased pressure during phlebotomy, small gauge needles, and multiple punctures. Cancer patients enrolled in a melanoma clinical study exhibited the clearest pattern of miRNA expression as compared to normal donors in both the rank-based analytical method and standard biostatistical array approaches. For the patients from the tumor banks, fewer miRNAs (<5) were found to be differentially expressed and the false positive rate was relatively high. Conclusion: In order to obtain consistent results for NanoString miRNA arrays, it is imperative that patient cohorts have similar clinical characteristics with a uniform sample preparation procedure. A clinical workflow has been optimized to collect patient samples to study plasma miRNAs.

Original languageEnglish (US)
Pages (from-to)5931-5941
Number of pages11
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - Sep 29 2016

Keywords

  • Melanoma
  • Profiling
  • Rank-based statistic
  • miRNA

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches'. Together they form a unique fingerprint.

Cite this